VBL Therapeutics to Present at the Chardan Gene Therapy Conference

TEL AVIV, Israel, Sept. 28, 2017 -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced Prof. Dror Harats, M.D., Chief Executive Officer, will provide a corporate overview via a Fireside Chat format at the Chardan Gene Therapy Conference, being held October 10th at the Westin New York Grand Central hotel in New York City.

Presentation Details:
Date:  Tuesday, October 10
Time:  1:45pm Eastern Time.
Webcast:  http://wsw.com/webcast/chard/vblt/

About VBL
Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company’s lead oncology product candidate, ofranergene obadenovec (VB-111), is a first-in-class biologic agent that uses a dual mechanism to target solid tumors. It utilizes an angiogenesis-specific sensor (VBL's PPE-1-3x proprietary promoter) to specifically target the tumor vasculature, by induction of cell death in angiogenic endothelial cells in the tumor milieu. Moreover, it is an immune-stimulant that triggers a local anti-tumor immune response, which is accompanied by recruitment of CD8 T-cells and apoptosis of tumor cells. Ofranergene obadenovec is positioned to treat a wide range of solid tumors and is conveniently administered as an IV infusion once every two months. It has been observed to be well-tolerated in >300 cancer patients and we have observed its efficacy signals in an “all comers” Phase 1 trial as well as in three tumor-specific Phase 2 studies. Ofranergene obadenovec is currently being studied in a Phase 3 pivotal trial for recurrent Glioblastoma, conducted under an FDA Special Protocol Assessment (SPA).

INVESTOR CONTACT:
Michael Rice
LifeSci Advisors, LLC
[email protected] 
(646) 597-6979

MEDIA CONTACT:
Matt Middleman, M.D.
LifeSci Public Relations
[email protected] 
(646) 627-8384